Manremyc, the spin-off created by the UTE to fight TB, raised 300,000€

Major partners of Manremyc

From left to right: Ms Isabel Amat, cofounder; Mr Joan Puig de Dou, investor; Dr Pere-Joan Cardona, head of the UTE, inventor of NR and cofounder; Mr Joan Puig Corcoy, investor; Dr Manel Puig-Domingo, director of the Institut Germans Trias; Dr Cris Vilaplana, coinventor of NR & cofounder of Manremyc; Mr Jaume Amat, cofounder.

The research conducted in our Unit lead to the generation of a new patent (Cardona, Vilaplana & Marzo, PCT/ES2013/000145) and the creation of a spin-off, Manremyc.  The company  is a spin-off of the Germans Trias i Pujol Foundation and the CIBER Enfermedades Respiratorias (from the ISCIII), with the aim to develop the revolutionary natural product designed to  modulate the immune response against TB:  the Nyaditum resae®.  Dr Pere-Joan Cardona is the CEO/CSO of this company.

Since now, Manremyc has already built a solid and accurate preclinical dossier and conducted a Clinical Trial (ClinicalTrials.gov Identifier: NCT02076139) to demonstrate the tolerability of the nutraceutical, which results will be disseminated in the 45th Union World Conference on Lung Health.

This summer, Manremyc has raised 300,000€ in its 2nd capital round, an amount that will permit the search of international partners  (basically in the Asia market and especially in India) to start selling Nyaditum resae® next year.

You can access the details of this new here:

Advertisements
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s